Free Trial

Petros Pharmaceuticals Q2 2023 Earnings Report

Petros Pharmaceuticals logo
$0.29 -0.02 (-5.67%)
(As of 12/20/2024 05:31 PM ET)

Petros Pharmaceuticals EPS Results

Actual EPS
-$1.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Petros Pharmaceuticals Revenue Results

Actual Revenue
$1.99 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Petros Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here << 

Petros Pharmaceuticals Earnings Headlines

If you see ONE chart today… make it this one
$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.
Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)
See More Petros Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Petros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Petros Pharmaceuticals and other key companies, straight to your email.

About Petros Pharmaceuticals

Petros Pharmaceuticals (NASDAQ:PTPI), a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

View Petros Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings